Regenera receives ethics approval for second clinical trial

By Renate Krelle
Wednesday, 20 October, 2004

Perth's Regenera (ASX: RGA) has received ethics approval for the second of five Phase III clinical trial to be conducted in Singapore using intravitreal injections of its product Visagen to treat macular oedema.

Visagen is a preservative free formulation of the steroid triamcinolone acetonide.

The trials will be conducted in conjunction with the Singapore Eye Research Institute, an arm of the Singapore National Eye Centre.

'Low-risk' antibiotic linked to rise of dangerous superbug

A new study has challenged the long-held belief that rifaximin — commonly prescribed to...

Robotic hand helps cultivate baby corals for reef restoration

The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...

Stem cell experiments conducted in space

Scientists are one step closer to manufacturing stem cells in space — which could speed up...

Content from other channels on our network

Rising healthcare facility demands pave way for innovation

Designs unveiled for the new Melton Hospital

AIA Australia launches virtual mental health service

Depressive disorders: 70% of Australians not getting adequate treatment

High blood pressure costs Australia $1.2bn a year

Making Australian canola oil more sustainable with solar power

Who will pay for emission reductions in the milk sector?

Fonterra charts progress against its 'Climate Roadmap'

How to manage safety risks in the low-moisture food sector?

Pure Dairy appoints new CCO

Making the national electricity market fit for purpose

Driving progress in clean energy

A first line of defence in wastewater screening

NSW initiative tackles food waste at the source

NSW celebrates recycling triumph